Kezar Life Sciences Inc (KZR)

Apr 03, 2025

Kezar Life Sciences stock hits 52-week low at $4.36 - Investing.com

Apr 03, 2025

Apr 02, 2025

Polymyositis Market Predicted to See Upsurge Through 2034, - openPR.com

Apr 02, 2025

Apr 01, 2025

Kezar Life Sciences Appoints New Principal Accounting Officer - TipRanks

Apr 01, 2025

Mar 29, 2025

What is William Blair’s Forecast for KZR Q1 Earnings? - Defense World

Mar 29, 2025

Mar 26, 2025

KZR stock touches 52-week low at $5.20 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

KZR stock touches 52-week low at $5.20 amid market challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results - BioSpace

Mar 26, 2025

Mar 25, 2025

Kezar reports positive AIH trial results, financials for 2024 By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Promising Clinical Trial Results and Safety Profile Justify Buy Rating for Kezar Life Sciences - TipRanks

Mar 25, 2025

Mar 25, 2025

Kezar stock drops on Q4 results, trial data (KZR:NASDAQ) - Seeking Alpha

Mar 25, 2025

Mar 25, 2025

Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate - Benzinga

Mar 25, 2025

Mar 25, 2025

Kezar reports positive AIH trial results, financials for 2024 - Investing.com India

Mar 25, 2025

Mar 25, 2025

Kezar Life Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

KEZAR LIFE SCIENCES Earnings Results: $KZR Reports Quarterly Earnings - Nasdaq

Mar 25, 2025

Mar 25, 2025

Breakthrough in Autoimmune Hepatitis: Kezar's Drug Achieves 36% Response Rate While Placebo Shows Zero - Stock Titan

Mar 25, 2025

Mar 24, 2025

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025 - BioSpace

Mar 24, 2025

Mar 24, 2025

Major Clinical Trial Results: New Autoimmune Hepatitis Treatment Shows PromiseData Reveal Coming - Stock Titan

Mar 24, 2025

Mar 23, 2025

Amundi Sells 74,019 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) - Defense World

Mar 23, 2025

Mar 17, 2025

KEZAR LIFE SCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 17, 2025

Mar 17, 2025

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Mar 17, 2025

Mar 16, 2025

How the (KZR) price action is used to our Advantage - news.stocktradersdaily.com

Mar 16, 2025

Mar 12, 2025

Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail

Mar 12, 2025

Mar 10, 2025

Kezar Life Sciences Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView

Mar 10, 2025

Mar 06, 2025

Kezar Life Sciences (KZR) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 06, 2025

Mar 03, 2025

Kezar Life Sciences’ (KZR) Outperform Rating Reiterated at William Blair - Defense World

Mar 03, 2025

Feb 28, 2025

Kezar stock rating raised to Outperform at William Blair By Investing.com - Investing.com UK

Feb 28, 2025

Feb 24, 2025

Dermatomyositis Market Generated Opportunities, Future Scope - openPR

Feb 24, 2025

Feb 23, 2025

(KZR) On The My Stocks Page - Stock Traders Daily

Feb 23, 2025

Feb 21, 2025

Kezar Life Sciences (KZR) Stock Price, News & Analysis - MarketBeat

Feb 21, 2025

Feb 21, 2025

Activist investor threatens Peninsula drug maker's merger plans - The Business Journals

Feb 21, 2025

Feb 18, 2025

Major Clinical Development Update: Stanford Expert Reveals Future of Zetomipzomib in Autoimmune Hepatitis - StockTitan

Feb 18, 2025

Feb 12, 2025

Objective long/short (KZR) Report - Stock Traders Daily

Feb 12, 2025

Feb 07, 2025

Kezar Life Sciences files for $400M mixed securities shelf - MSN

Feb 07, 2025

Feb 06, 2025

Autoimmune Hepatitis Market Growth to Accelerate in Forecast - openPR

Feb 06, 2025

Feb 05, 2025

Kezar Life Sciences Files $400 Million Mixed Securities Shelf -February 05, 2025 at 05:55 pm EST - Marketscreener.com

Feb 05, 2025

Jan 15, 2025

Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update - Defense World

Jan 15, 2025

Jan 13, 2025

Kezar reports preliminary year-end financial position - Investing.com

Jan 13, 2025

Dec 21, 2024

Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World

Dec 21, 2024

Dec 05, 2024

HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World

Dec 05, 2024

Dec 04, 2024

Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat

Dec 04, 2024

Dec 03, 2024

Kezar Life Sciences updates shareholder rights agreement - Investing.com

Dec 03, 2024

Dec 03, 2024

Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World

Dec 03, 2024

Nov 18, 2024

William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat

Nov 18, 2024

Nov 18, 2024

FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World

Nov 18, 2024

Nov 18, 2024

Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World

Nov 18, 2024

Nov 16, 2024

Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World

Nov 16, 2024

Nov 13, 2024

Kezar struck again with second FDA hold - Clinical Trials Arena

Nov 13, 2024

Nov 13, 2024

Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Nov 13, 2024

Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat

Nov 13, 2024

Nov 13, 2024

Kezar’s Autoimmune Drug Hit With Second FDA Clinical Hold in as Many Months - BioSpace

Nov 13, 2024

Nov 12, 2024

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire

Nov 12, 2024